UBS maintains $74 target on Williams Companies stock

UBS reiterated a Buy rating with a $74 price target on Williams Companies (WMB), highlighting the anticipated progress of its pipeline projects, particularly the Northeast Supply Enhancement (NESE) project slated for construction in Q3 2025 and operation by Q4 2027. While the NESE project is viewed as more likely to proceed than the Constitution pipeline due to simpler permitting, Williams is seeking partners for the latter's development; recent analyst ratings are mixed, with Wells Fargo and Raymond James issuing Overweight/Outperform ratings, while CFRA downgraded WMB to Hold due to valuation concerns, despite a slightly better than expected Q1 2025 earnings report showing an adjusted EBITDA of $1.989 billion.

Analysis

Williams Companies (WMB) has received a reiterated Buy rating and a $74.00 price target from UBS, primarily driven by strategic pipeline projects, notably the fully-owned Northeast Supply Enhancement (NESE) project scheduled for construction in Q3 2025 and in-service by Q4 2027. Management views NESE as more probable than the Constitution pipeline (targeted for July 2027 in-service) due to simpler permitting, with WMB seeking partners for the latter's development, highlighting a potential collaboration with the Millennium pipeline. This infrastructure focus is complemented by strong Q1 2025 financial results, where adjusted EBITDA reached $1.989 billion, surpassing analyst estimates, and available funds from operations exceeded expectations, aligning with the company's strong dividend growth rate. Analyst sentiment is largely positive, with Wells Fargo projecting an 11% three-year compound annual growth rate in EBITDA and maintaining an Overweight rating ($67 PT), while RBC Capital Markets (Outperform, $63 PT), Stifel (PT to $63), and Raymond James (Outperform, $64 PT) also issued favorable outlooks citing robust growth, strategic initiatives like the Socrates project, and solid operational strategy. However, CFRA issued a contrasting view, downgrading WMB from Buy to Hold with a $62 price target due to valuation concerns, despite increasing its 2025 earnings per share estimate to $2.15. The company is also navigating a CEO transition and ongoing strategic evaluations, which are key factors for investor monitoring.

Key Decisions for Investors

• Investors should closely monitor the execution and regulatory approval timelines for the NESE and Constitution pipeline projects, as their successful completion is central to WMB's growth narrative and UBS's $74 price target.
• Consider the balance between WMB's strong Q1 2025 operational performance, positive EBITDA growth outlook, and supportive analyst ratings against CFRA's valuation-driven downgrade to Hold when assessing entry or exit points.
• Remain attentive to developments surrounding the CEO transition and any announcements from ongoing strategic evaluations, as these could impact project prioritization, capital allocation, and partnership strategies for key assets like the Constitution pipeline.